51. In silico estrogen-like activity and in vivo osteoclastogenesis inhibitory effect of Cicer arietinum extract.
- Author
-
Sayed AA and Elfiky AA
- Subjects
- Alendronate chemistry, Alendronate pharmacology, Animals, Bone Density Conservation Agents chemistry, Bone Density Conservation Agents isolation & purification, Bone Density Conservation Agents pharmacology, Calcium-Binding Proteins antagonists & inhibitors, Calcium-Binding Proteins genetics, Calcium-Binding Proteins metabolism, Disease Models, Animal, Estradiol chemistry, Estradiol pharmacology, Estrogen Receptor alpha agonists, Estrogen Receptor alpha metabolism, Estrogen Receptor beta agonists, Estrogen Receptor beta metabolism, Female, Gene Expression Regulation, Genistein chemistry, Genistein isolation & purification, Genistein pharmacology, Humans, Isoflavones chemistry, Isoflavones isolation & purification, Isoflavones pharmacology, Membrane Glycoproteins antagonists & inhibitors, Membrane Glycoproteins genetics, Membrane Glycoproteins metabolism, Molecular Docking Simulation, Osteogenesis genetics, Osteoporosis genetics, Osteoporosis metabolism, Osteoporosis pathology, Osteoprotegerin agonists, Osteoprotegerin genetics, Osteoprotegerin metabolism, Ovariectomy, Phytoestrogens chemistry, Phytoestrogens isolation & purification, Protein Structure, Secondary, RANK Ligand agonists, RANK Ligand genetics, RANK Ligand metabolism, Rats, Receptors, Cytoplasmic and Nuclear antagonists & inhibitors, Receptors, Cytoplasmic and Nuclear genetics, Receptors, Cytoplasmic and Nuclear metabolism, Receptors, Peptide antagonists & inhibitors, Receptors, Peptide genetics, Receptors, Peptide metabolism, Cicer chemistry, Estrogen Receptor alpha genetics, Estrogen Receptor beta genetics, Osteogenesis drug effects, Osteoporosis drug therapy, Phytoestrogens pharmacology, Phytotherapy
- Abstract
Postmenopausal osteoporosis is a common disorder accompanied with estrogen deficiency in women. Plants containing phytoestrogens and amino acids have been used in the osteoporosis treatment. The present study aims to evaluate the estrogen-like activity of the Cicer arietinum extract (CAE) and its ability to inhibit osteoclastogenesis process. These achieved by investigating the binding of its active phytoestrogens (genistein, daidzein, formononetin and biochanin A) to the estrogen receptors (ER) α and β of rats and human in silico. In addition, in vivo study on ovariectomized (OVX) rats is performed. For in vivo study, twenty four rats were divided into four groups (n= 6). Group I is the sham control rats which administered distilled water. Groups II, III, and IV are OVX groups which administered distilled water, CAE (500 mg/kg), and alendronate; respectively. The docking study revealed that the phytoestrogens docked into the protein active site with binding energies comparable with that of estrogens (estriol and β-estradiol) which means the similarity between the estrogenic contents of CAE and the ensogenous ones. Additionally, in vivo study revealed that CAE reverse TRAP5b and RANKL levels that drastically increased in the untreated OVX group. But, it trigger upregulation of OPG, enhance the OPG/RANKL ratio and modulate the bone and uterus alterations of OVX group. Phytoestrogens and the bone-protective amino acids contents of CAE could be responsible for their estrogen-like effect and antiosteoporotic activity. These results concluded that CAE is an attractive candidate for developing a potential therapeutic cheap agent used as an alternative to the synthetic estrogen replacement therapy. Further, in vivo validation is required for its clinical application.
- Published
- 2018